close
Jump to content

LAMPA

Add links
From Wikipedia, the free encyclopedia

LAMPA
BERJAYA
BERJAYA
Clinical data
Other namesLysergic acid methylpropylamide; LMP; LAMP; LAMPA; LMP-55; LMP55; MPLA; N-Methyl-N-propyllysergamide; N,6-Dimethyl-N-propyl-9,10-didehydroergoline-8β-carboxamide
Legal status
Legal status
Identifiers
  • N,7-dimethyl-N-propyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H25N3O
Molar mass323.440 g·mol−1
3D model (JSmol)
  • CCCN(C)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C
  • InChI=1S/C20H25N3O/c1-4-8-22(2)20(24)14-9-16-15-6-5-7-17-19(15)13(11-21-17)10-18(16)23(3)12-14/h5-7,9,11,14,18,21H,4,8,10,12H2,1-3H3
  • Key:CZRJGQXHVRNZRZ-UHFFFAOYSA-N

Lysergic acid methylpropylamide (LAMPA, LAMP, or LMP), also known as LMP-55 or as N-methyl-N-propyllysergamide (MPLA), is a structural analogue of lysergic acid diethylamide (LSD) that has been studied as a potential treatment for alcoholism.[1] In animal studies, LAMPA was found to be nearly equipotent to ECPLA and MIPLA for inducing a head-twitch response. LAMPA appears to be significantly less potent than LSD in humans, producing little to no noticeable effects at doses of 100 μg.[2] It shows reduced-efficacy partial agonism of the serotonin 5-HT2A receptor relative to LSD, which may be responsible for its equivocal hallucinogenic effects.[3] LAMPA is not an explicitly controlled substance in the United States,[4] but may be considered implicitly controlled as it is an isomer of LSD.[5][6] The drug is not a controlled substance in Canada as of 2025.[7]

See also

[edit]

References

[edit]
  1. ↑ Abramson HA, Rolo A (1967). "Comparison of LSD with methysergide and psilocybin on test subjects." (PDF). In Abramson HA (ed.). The use of LSD in psychotherapy and alcoholism. Bobbs-Merrill Company Inc. pp. 53–57. Retrieved 15 May 2022.
  2. ↑ Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, et al. (February 2019). "Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)". Psychopharmacology. 236 (2): 799–808. doi:10.1007/s00213-018-5055-9. PMC 6848745. PMID 30298278.
  3. ↑ Pottie E, Glatfelter GC, Baumann MH, Stove CP (2024). "Differential in Vitro Activation Profiles for Psychedelic versus Non-psychedelic Ergolines at the 5-HT2A Receptor". Emerging Trends in Drugs, Addictions, and Health. 4 100109. doi:10.1016/j.etdah.2023.100109.
  4. ↑ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
  5. ↑ Wachełko O, Nowak K, Tusiewicz K, Zawadzki M, Szpot P (January 2025). "A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies". Analyst. 150 (2): 290–308. doi:10.1039/d4an01361a. PMID 39636448.
  6. ↑ Drug Enforcement Administration (3 December 2007). "Definition of "Positional Isomer" as It Pertains to the Control of Schedule I Controlled Substances". Federal Register.
  7. ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=LAMPA&oldid=1361896970"